Goldman Sachs Group Inc Puma Biotechnology, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 294,243 shares of PBYI stock, worth $994,541. This represents 0.0% of its overall portfolio holdings.

Number of Shares
294,243
Previous 294,243 -0.0%
Holding current value
$994,541
Previous $870,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$2.76 - $3.88 $54,797 - $77,033
-19,854 Reduced 6.32%
294,243 $870,000
Q4 2024

Feb 11, 2025
BUY
$2.42 - $3.39 $20,277 - $28,404
8,379 Added 2.74%
314,097 $957,000
Q3 2024

Nov 14, 2024
BUY
$2.25 - $4.03 $236,551 - $423,690
105,134 Added 52.41%
305,718 $779,000
Q2 2024

Aug 13, 2024
SELL
$2.92 - $5.83 $729,988 - $1.46 Million
-249,996 Reduced 55.48%
200,584 $653,000
Q1 2024

May 15, 2024
BUY
$4.29 - $7.4 $1.44 Million - $2.48 Million
334,625 Added 288.58%
450,580 $2.39 Million
Q4 2023

Feb 13, 2024
BUY
$2.23 - $4.49 $70,938 - $142,831
31,811 Added 37.81%
115,955 $502,000
Q3 2023

May 14, 2024
SELL
$2.63 - $4.09 $83,662 - $130,106
-31,811 Reduced 27.43%
84,144 $221,000
Q3 2023

Nov 14, 2023
BUY
$2.63 - $4.09 $26,904 - $41,840
10,230 Added 13.84%
84,144 $221,000
Q2 2023

May 14, 2024
SELL
$2.6 - $3.58 $234 - $322
-90 Reduced 0.12%
73,914 $260,000
Q2 2023

Aug 14, 2023
SELL
$2.6 - $3.58 $234 - $322
-90 Reduced 0.12%
73,914 $260,000
Q1 2023

May 14, 2024
SELL
$2.21 - $4.82 $5,407 - $11,794
-2,447 Reduced 3.2%
74,004 $228,000
Q1 2023

May 11, 2023
SELL
$2.21 - $4.82 $5,407 - $11,794
-2,447 Reduced 3.2%
74,004 $228,000
Q4 2022

May 14, 2024
SELL
$2.12 - $5.08 $91,331 - $218,851
-43,081 Reduced 36.04%
76,451 $323,000
Q4 2022

Feb 13, 2023
SELL
$2.12 - $5.08 $91,331 - $218,851
-43,081 Reduced 36.04%
76,451 $323,000
Q3 2022

May 14, 2024
SELL
$2.27 - $3.84 $230,087 - $389,222
-101,360 Reduced 45.89%
119,532 $284,000
Q3 2022

Nov 10, 2022
SELL
$2.27 - $3.84 $230,087 - $389,222
-101,360 Reduced 45.89%
119,532 $0
Q2 2022

May 14, 2024
BUY
$1.64 - $3.3 $172,096 - $346,292
104,937 Added 90.5%
220,892 $629,000
Q2 2022

Aug 15, 2022
SELL
$1.64 - $3.3 $359,064 - $722,508
-218,942 Reduced 49.78%
220,892 $629,000
Q1 2022

May 16, 2022
SELL
$2.13 - $3.24 $3.93 Million - $5.97 Million
-1,843,331 Reduced 80.74%
439,834 $1.27 Million
Q4 2021

Feb 14, 2022
BUY
$2.85 - $6.58 $4.2 Million - $9.71 Million
1,475,239 Added 182.6%
2,283,165 $6.94 Million
Q3 2021

Nov 10, 2021
BUY
$6.63 - $9.39 $5.36 Million - $7.59 Million
807,926 New
807,926 $5.66 Million

Others Institutions Holding PBYI

# of Institutions
116
Shares Held
30.9M
Call Options Held
32.7K
Put Options Held
200
View Full List

About PUMA BIOTECHNOLOGY, INC.

PBYI Quotes by TradingView
  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $154M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email